AutonomyNCT04619420
A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 75 versions: 32 with changes below, 18 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Results posted: Nov 5, 2026 Show 4 more changesShow less
- Eligibility criteria expanded, about 10 words
- Primary endpoint revised
- Secondary endpoints: 21 to 25
- Site details revised at 4 of 122 sites
- Stopped Trial terminated Sponsor's reason: Posdinemab did not achieve statistical significance in slowing clinical decline
- Study completion date changed from estimate of Mar 8, 2026 to Mar 3, 2026
- Minor Study sites revised (122)v73
- Minor Study completion date: Dec 30, 2032 to Mar 8, 2026v72
- Minor Primary completion date changed from estimate of Feb 27, 2026 to Oct 17, 2025v70
Show 27 earlier versionsHide 27 earlier versions
- Minor Site details revised at 1 of 122 sitesv63
- Minor Study sites revised (122)v58
- Minor Site details revised at 2 of 122 sitesv56
- Minor Study sites revised (122)v54
- Minor Study sites revised (122)v52
- Minor Primary completion date: Nov 28, 2025 to Feb 27, 2026
- Study sites revised (122)
- Minor Site details revised at 1 of 122 sitesv48
- Notable Primary completion date: Mar 7, 2025 to Nov 28, 2025
- Secondary endpoints revised (21)
- Minor Study sites revised (122)v46
- Minor Study sites revised (122)v45
- Minor Study completion date: Dec 1, 2025 to Dec 30, 2032v44
- Minor Secondary endpoints: 20 to 21
- Site details revised at 1 of 122 sites
- Study arms: 2 to 3
- Minor Study completion date: Nov 5, 2025 to Dec 1, 2025v42
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 480 to confirmed 523
- Site details revised at 122 of 122 sites
- Minor Study sites revised (122)v40
- Minor Site details revised at 2 of 122 sitesv39
- Minor Site details revised at 8 of 122 sitesv38
- Minor Study sites revised (122)v37
- Minor Site details revised at 2 of 122 sitesv36
- Minor Enrollment target: 420 to 480
- Study sites: 144 to 122
- Minor Site details revised at 1 of 144 sitesv33
- Minor Study sites revised (144)v31
- Minor Site details revised at 5 of 144 sitesv30
- Minor Site details revised at 1 of 144 sitesv29
- Minor Study sites revised (144)v28
- Minor Site details revised at 7 of 144 sitesv27
- Minor Site details revised at 10 of 144 sitesv26
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (25)
Show 20 moreShow less
Arms and interventions
Participants will receive single dose of JNJ-63733657 low-dose administered by intravenous (IV) infusion every 4 weeks during the double-blind treatment period. Participants will have an option to continue with the long-term extension (LTE) phase of the trial and will continue to receive the same treatment and dose during the LTE treatment period.
Participants will receive single dose of JNJ-63733657 high-dose administered by IV infusion every 4 weeks during double-blind treatment period. Participants will have an option to continue with the LTE phase of the trial and will continue to receive the same treatment and dose during the LTE treatment period.
Participants will receive single dose of matching placebo to JNJ-63733657 administered by IV infusion every 4 weeks during double-blind treatment period. Participants will have an option to continue with the LTE phase of the trial and will be re-randomized in a 1:1 ratio to receive either JNJ-63733657 low-dose or JNJ-63733657 high-dose during the LTE treatment period.
Drugs: JNJ-63733657, Placebo
Sites
122 sites in 10 countries
United States 55, Japan 22, France 9, Spain 9, Belgium 8, Australia 7, Canada 5, Netherlands 4, United Kingdom 2, Sweden 1